Evaluating Open Weighing and Blind Weighing in the Treatment of Adolescents and Young Adults With Eating Disorders
Abstract
Current treatments for adolescents and young adults (AYAs) with eating disorders (EDs) do not effectively address a central ED symptom - anxiety about weight gain - which contributes to poor outcomes. The proposed study evaluates the feasibility, acceptability, efficacy, and underlying mechanisms of an enhanced version of "open weighing," a cognitive-behavioral intervention designed to target anxiety about weight gain in AYAs with EDs. Understanding how to better treat AYAs with EDs, and identifying the mechanisms by which interventions lead to improvement, will aid in the development of more effective and personalized treatments, ultimately improving the lives of AYAs with EDs.
Conditions: Eating Disorders, Anorexia Nervosa.
Primary outcome: Eating Disorder Examination - Self-Report Questionnaire (EDE-Q); Fear of Food Measure (FOFM); Body Shape Questionnaire (BSQ); Clinical Impairment Assessment (CIA); Eating Disorder Fear Questionnaire (EDFQ); Eating Disorder-15 (ED 15); Body Image States Scale (BISS); Approach / Avoidance of weighing Questionnaire (AAWQ); Eating Disorder Examination - Self-Report Questionnaire (EDE-Q); Fear of Food Measure (FOFM); Body Shape Questionnaire (BSQ); Clinical Impairment Assessment (CIA); Eating Disorder Fear Questionnaire (EDFQ); Eating Disorder-15 (ED-15); Body Image State Scale (BISS); Approach / Avoidance of Weighing Questionnaire (AAWQ).
Enrollment: 70 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 70 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.